Trial Profile
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2020
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Chlorambucil; Etoposide; Lomustine; Prednisone; Rituximab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 08 Dec 2015 Status changed from active, no longer recruiting to completed, as per an abstract presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 13 May 2009 New trial record